Ultragenyx Pharmaceutical Inc.

NASDAQ:RARE  
48.64
+2.80 (+6.11%)
Other Pre-Announcement

Ultragenyx Pharmaceutical Q1 Loss Per Share $2.19

Published: 05/05/2022 21:16 GMT
Ultragenyx Pharmaceutical Inc. (RARE) - Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update.
Q1 2022 Total Revenue of $79.9 Million and Crysvita Revenue in Ultragenyx Territories of $54.6 Million.
Q1 Loss per Share $2.19.
Expect 2022 Revenue for Crysvita in Ultragenyx Territories to Be Between $250 Million and $260 Million.
Sees Dojolvi Revenue to Be Between $55 Million and $65 Million in 2022.
Q1 Earnings per Share View $-1.76, Revenue View $83.7 Million -- Refinitiv Ibes Data (analyst estimates).
FY2022 Revenue View $374.4 Million -- Refinitiv Ibes Data (analyst estimates).